Tarsus Pharmaceuticals, Inc., the biopharmaceutical company known for applying proven science and new technology to revolutionize patient treatment, has closed a $60.0M Series B funding round.
The capital infusion will bolster the NASDAQ-listed firm (TARS) as it continues to advance its pipeline, with an initial and significant focus on eye care. Tarsus aims to identify and address unmet needs in patient care by leveraging established scientific principles to develop innovative and effective therapeutic solutions.















